NCT02145403 2022-01-03Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic MalignanciesUniversity of Michigan Rogel Cancer CenterPhase 1/2 Completed53 enrolled 17 charts
NCT01949545 2017-05-02Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic ImpairmentAmgenPhase 1 Completed46 enrolled 45 charts